Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
Crocetto F, Ferro M, Buonerba C, Bardi L, Dolce P, Scafuri L, Mirto BF, Verde A, Sciarra A, Barone B, Calogero A, Sagnelli C, Busetto GM, Del Giudice F, Cilio S, Sonpavde G, Di Trolio R, Della Ratta GL, Barbato G, Di Lorenzo G. Crocetto F, et al. Among authors: sonpavde g. Crit Rev Oncol Hematol. 2023 Aug;188:104059. doi: 10.1016/j.critrevonc.2023.104059. Epub 2023 Jun 21. Crit Rev Oncol Hematol. 2023. PMID: 37353178 Review.
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, Sonpavde G, Musi G, Antonelli A, Veccia A, Terracciano D, Busetto GM, Del Giudice F, Marchioni M, Schips L, Porpiglia F, Fiori C, Carrieri G, Lasorsa F, Verde A, Scafuri L, Buonerba C, Di Lorenzo G. Ferro M, et al. Among authors: sonpavde g. Clin Genitourin Cancer. 2023 Oct;21(5):574-583. doi: 10.1016/j.clgc.2023.05.017. Epub 2023 May 27. Clin Genitourin Cancer. 2023. PMID: 37419854
Muscle invasive bladder cancer: where is the field headed?
Ghatalia P, Kaur J, Sonpavde G. Ghatalia P, et al. Among authors: sonpavde g. Expert Opin Biol Ther. 2023 Jul-Dec;23(9):913-927. doi: 10.1080/14712598.2023.2238607. Epub 2023 Jul 21. Expert Opin Biol Ther. 2023. PMID: 37477127 Review.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J. McGregor BA, et al. Among authors: sonpavde gp. Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Clinical Trial.
Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
Riveros C, Ranganathan S, Haque W, Huang E, Xu J, Kulkarni GS, Geng M, Anis M, Muhammad T, Chan KS, Farach A, Teh BS, Miles BJ, Klaassen Z, Sonpavde GP, Wallis CJD, Satkunasivam R. Riveros C, et al. Among authors: sonpavde gp. Can Urol Assoc J. 2024 Feb;18(2):17-24. doi: 10.5489/cuaj.8386. Can Urol Assoc J. 2024. PMID: 37931278 Free PMC article.
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Singh AM, et al. Among authors: sonpavde g. BioDrugs. 2023 Jul;37(4):505-520. doi: 10.1007/s40259-023-00606-5. Epub 2023 May 31. BioDrugs. 2023. PMID: 37256534 Review.
489 results